In the treatment ofadvanced prostate cancer (APC)
Why Wait to Lower Testosterone?
FIRMAGON®, the GnRH receptor antagonist, is the only ADT proven to drop T by 88% on day 1
PRIMARY ENDPOINT: FIRMAGON maintained testosterone suppression below castration level (≤50 ng/dL) over 364 days of treatment.3View Study Data
Learn about FIRMAGON through
a self-guided interactive video
FIRMAGON is approved for all stages of APC
FIRMAGON is proven to suppress T in all stages of APC3Learn More
Abbreviations: APC = advanced prostate cancer; GnRH = gonadotropin-releasing hormone; T = testosterone.
REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Data on file. Ferring Pharmaceuticals Inc. 3. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. 4. American Cancer Society. Hormone therapy for prostate cancer; 2016. https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html. Accessed July 11, 2017. 5. Huggins C., Hodges C.. Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in MetastaticCarcinoma of the Prostate* Department of Surgery, the University of Chicago 1941;1:293-297.